COVID lung damage: who gets scarred?
NCT ID NCT04987528
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 ICU patients with severe COVID-19 to see how often they develop lung scarring (pulmonary fibrosis). Researchers will use blood tests and CT scans to find early signs of scarring and identify risk factors. The goal is to understand how scarring affects recovery and survival, which could improve care for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which COVID-19 patients are at risk of permanent lung damage and guide follow-up care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Europeen Marseille
Marseille, 13003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?
- Could a spirometer test guide breathing support in respiratory failure?
- Which ventilator setting saves more lungs? a Head-to-Head test